Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Panel Looks Beyond Xarelto’s Missing Data Problems To Broader Reforms

Jun 04 2012

• By Sue Sutter

Related Content

Cardiovascular Outcomes Trials Increasingly Complicated By Missing Data

Aug 16 2010

Industry, FDA Face Changes In Handling Of Missing Clinical Trial Data

Aug 16 2010

<em>Xarelto</em> Acute Coronary Syndromes Claim Faces Data Quality Hurdle

May 22 2012

FDA Advice On Missing Data May Be To Avoid Missing It In The First Place

Mar 01 2012

ATLAS Data Not Strong Enough To Support <em>Xarelto</em>’s Use In ACS, FDA Panel Says

May 28 2012

ATLAS Trial Design Blamed For Missing Data On <em>Xarelto</em> ACS Use

Jun 04 2012

Related Companies

Johnson & Johnson

Bayer AG

AstraZeneca PLC

GSK plc

Additional Topics

Clinical Trials Advisory Committees Regulation BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window